ES2075900T3 - Composiciones estables de vacuna que contienen interleucinas. - Google Patents

Composiciones estables de vacuna que contienen interleucinas.

Info

Publication number
ES2075900T3
ES2075900T3 ES90911344T ES90911344T ES2075900T3 ES 2075900 T3 ES2075900 T3 ES 2075900T3 ES 90911344 T ES90911344 T ES 90911344T ES 90911344 T ES90911344 T ES 90911344T ES 2075900 T3 ES2075900 T3 ES 2075900T3
Authority
ES
Spain
Prior art keywords
vaccine compositions
compositions containing
interleukin
mineral
interleukins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911344T
Other languages
English (en)
Inventor
Subramonia Pillai
Garvin Bixler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2075900T3 publication Critical patent/ES2075900T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION DESCRIBE COMPOSICIONES DE VACUNAS CONTENIENDO INTERLEUCINAS , COMPRENDIENDO UNA MEZCLA DE ANTIGENO Y UNA CANTIDAD ADYUVANTE DE UNA INTERLEUCINA ABSORVIDA EN UN MINERAL EN SUSPENSION Y UN PRESERVATIVO. PREFERENTEMENTE, EL MINERAL ES ALUMINIO. LA INTERLEUCINA PUEDE MODULAR LA RESPUESTA INMUNOPROTECTORA A UN ANTIGENO, MIENTRAS QUE EL MINERAL ESTABILIZA LA ACTIVIDAD BIOLOGICA DE LA INTERLEUCINA.
ES90911344T 1989-07-14 1990-07-16 Composiciones estables de vacuna que contienen interleucinas. Expired - Lifetime ES2075900T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14

Publications (1)

Publication Number Publication Date
ES2075900T3 true ES2075900T3 (es) 1995-10-16

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911344T Expired - Lifetime ES2075900T3 (es) 1989-07-14 1990-07-16 Composiciones estables de vacuna que contienen interleucinas.

Country Status (12)

Country Link
EP (1) EP0482076B1 (es)
JP (2) JP3485184B2 (es)
KR (1) KR0177179B1 (es)
AT (1) ATE121629T1 (es)
AU (1) AU648509B2 (es)
CA (1) CA2063587C (es)
DE (1) DE69018990T2 (es)
DK (1) DK0482076T3 (es)
ES (1) ES2075900T3 (es)
FI (1) FI104233B (es)
NO (1) NO301577B1 (es)
WO (1) WO1991001143A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
CZ119993A3 (en) * 1990-12-19 1994-02-16 Schering Corp The use of il-4 for increasing immune response to immunogens in vaccines
CA2109316A1 (en) * 1991-05-13 1992-11-14 Edward Abraham Liposomal polysaccharide vaccines
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
ES2262181T3 (es) * 1996-05-31 2006-11-16 National University Of Ireland, Maynooth Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1813701A (en) 1999-12-03 2001-06-12 Celltech Chiroscience Limited Interleukin-1 muteins useful as vaccine adjuvants
JP2009500457A (ja) 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法
ES2374648T3 (es) * 2005-09-30 2012-02-20 Lipoxen Technologies Limited Composiciones de vacunas liposómicas que comprenden un antígeno polisacárido y un adyuvante proteico.
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
AU2008226974B2 (en) * 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
ES2641375T3 (es) * 2012-11-02 2017-11-08 Cytuvax Composición que comprende macroagregados de citoquinas
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合***的方法
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2022093718A1 (en) 2020-10-26 2022-05-05 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
CA3195594A1 (en) 2020-11-05 2022-05-12 Byung Ha Lee Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
CA2063587C (en) 2005-08-30
DE69018990D1 (de) 1995-06-01
DK0482076T3 (da) 1995-07-17
AU648509B2 (en) 1994-04-28
JPH04506663A (ja) 1992-11-19
JP2004002463A (ja) 2004-01-08
NO920161L (no) 1992-03-05
FI104233B1 (fi) 1999-12-15
AU6050090A (en) 1991-02-22
ATE121629T1 (de) 1995-05-15
NO920161D0 (no) 1992-01-13
WO1991001143A1 (en) 1991-02-07
FI104233B (fi) 1999-12-15
EP0482076B1 (en) 1995-04-26
JP3485184B2 (ja) 2004-01-13
EP0482076A1 (en) 1992-04-29
DE69018990T2 (de) 1995-12-14
CA2063587A1 (en) 1991-01-15
KR920703103A (ko) 1992-12-17
FI920132A0 (fi) 1992-01-13
KR0177179B1 (ko) 1999-03-20
NO301577B1 (no) 1997-11-17

Similar Documents

Publication Publication Date Title
ES2075900T3 (es) Composiciones estables de vacuna que contienen interleucinas.
FI945483A (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
DK400181A (da) Sammensatte materialer indeholdende immobiliserede biologisk aktive arter fremgangsmaade til deres fremstilling samt deres anvendelse
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
ES2092306T3 (es) Adyuvante para vacunas.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
DK0787112T3 (da) Aerogelholdig sammensætning, fremgangsmåde til dens fremstilling samt dens anvendelse
MX9803290A (es) Composiciones de la vacuna influenza.
DE3482907D1 (de) Verwendung des diterpen-derivates forskolin zur immunstimulation.
ES2109254T3 (es) Proteinas antigenas y vacunas que las contienen para la prevencion de cocidiosis.
PT90710A (pt) Processo para a preparacao de silica para composicoes dentifricas compativel designadamente com zinco
ATE61937T1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
SE8404707L (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
EP0722338A4 (en) PROTEIN OR PEPTIDE COCHLEATE VACCINES AND IMMUNIZATION METHODS USING THE SAME
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
JPS57116100A (en) Novel d-homosteroid
JPS55106261A (en) Composition made of dispersed body of colloid silica and colloid titania
ES2056378T3 (es) Procedimiento de extraccion.
GB2227936A (en) Vaccine against brucella abortus
GR1000881B (el) Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
ATE102038T1 (de) Eliminierung von aktivierten lymphozyten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 482076

Country of ref document: ES